Durable remissions in TCF3-HLF positive acute lymphoblastic leukemia with blinatumomab and stem cell transplantation

Brice Mouttet, Luciana Vinti, Philip Ancliff, Nicole Bodmer, Benoît Brethon, Gunnar Cario, Christiane Chen-Santel, Sarah Elitzur, Volkan Hazar, Joachim Kunz, Anja Mörcke, Jerry Stein, Ajay Vora, Yöntem Yaman, Martin Schrappe, Sema Anak, André Baruchel, Franco Locatelli, Arend von Stackelberg, Martin Stanulla, and Jean-Pierre Bourquin

Disclosures: A.v.S. has received honoraria for invited presentations and has participated at advisory boards organized by Amgen, and has participated at advisory boards of the companies Novartis, Pfizer, Roche, Jazz-Pharmaceuticals and Morphosys. F.L. has received honoraria for invited presentations and has participated at advisory boards organized by Amgen. The other authors declare no competing financial interests.

Contributions: B.M. and JP.B. designed and performed the research, analyzed the data, and wrote the paper; L.V., P.A., N.B., B.B., C.CS., S.E., V.H., J.K., J.S., A.V., Y.Y., S.A., A.B., F.L., A.v.S., M.S. JP.B. managed treatment, provided data and reviewed the manuscript; G.C. A.M. and M.Sch. provided data and reviewed the manuscript; all authors read and approved the final manuscript.